New drug cocktail aims to outsmart resistant lung cancer
Disease control
Not yet recruiting
This phase 4 trial tests whether combining two oral drugs—ensartinib and anlotinib—can shrink tumors or slow disease in people with ALK-positive non-small cell lung cancer that has become resistant to lorlatinib. About 80 adults with advanced (stage IIIB-IV) cancer will receive t…
Phase: PHASE4 • Sponsor: Qiming Wang • Aim: Disease control
Last updated Jun 28, 2026 00:00 UTC